A range of spinal cord stimulators have been approved by the FDA, but none specifically for SCI patients. Abbott, Medtronic and Boston Scientific all have products indicated for chronic pain.
GlobalData on MSN3d
Globus Medical strengthens SCS market position with $250m Nevro dealGlobalData senior medical device analyst says the acquisition could see Nevro’s growth outside the US accelerate.
Hosted on MSN6mon
Boston Scientific (BSX) Banks on Global Expansion, InnovationWithin Neuromodulation, Boston Scientific’s pain business is consistently gaining traction, banking on strength in Spinal cord stimulation (SCS), driven by its innovative Alpha portfolio with ...
Boston Scientific Co. (NYSE:BSX – Get Free Report) has been given an average recommendation of “Buy” by the twenty-three ...
Boston Scientific (NYSE:BSX – Get Free Report) had its price objective hoisted by research analysts at Stifel Nicolaus from ...
Boosting communication between the spinal nerves and the muscles using the spinal cord stimulation reverses spinal muscle ...
14d
Therapeutic breakthroughs in neuromodulation merge wearable technologies, deep brain implants, and tailored stimulations ...
Spinal Cord Stimulators Market. The global spinal cord stimulators market is on an accelerated growth path, projected to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback